067630 — HLB Life Science Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩2tn
- KR₩2tn
- KR₩100bn
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 194,791 | 175,756 | 158,034 | 139,961 | 128,271 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 34,241 | 40,735 | 19,821 | 14,464 | 17,301 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 239,086 | 223,667 | 181,329 | 156,822 | 160,776 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 747 | 23,056 | 22,935 | 22,081 | 92,089 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 386,255 | 404,935 | 327,197 | 270,800 | 411,790 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 48,639 | 39,845 | 17,865 | 13,536 | 26,785 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 167,170 | 71,112 | 40,016 | 24,611 | 177,065 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 219,086 | 333,823 | 287,181 | 246,189 | 234,725 |
Total Liabilities & Shareholders' Equity | 386,255 | 404,935 | 327,197 | 270,800 | 411,790 |
Total Common Shares Outstanding |